AI startup Lunit from South Korea has bagged $26 million in a Series C Tranche B funding round. The investment came from Guardant Health, a Nasdaq-listed precision oncology firm.
WHAT IT DOES
Founded in 2013, Lunit develops AI software in the oncology space. Its solutions are designed to discover cancer and predict cancer treatment outcomes.
One of its tech solutions, tissue analysis platform...
Biotechnology firm AVATAMED and the Institute of Molecular and Cell Biology of Singapore's Agency for Science, Technology and Research have set up a joint lab in Biopolis, the city-state's biotechnology hub.
WHY IT MATTERS
Aiming to enhance treatment outcome for cancer patients, the joint service lab will offer both drug screening solutions of IMCB and AVATAMED to oncologists and pharmaceutical...
Sema4, a Mount Sinai spinout developing health-data-analytics platforms, has raised $121 million in Series C funding. BlackRock led the oversubscribed round, which also saw participation from new investors Deerfield Management Company and Moore Strategic Ventures, and also old backers Blackstone, Section 32, Oak HC/FT, Decheng and Connecticut Innovations.
With this round, coming less than a year...
Cancer has been the leading cause of death in Japan since 1981 and this is compounded by the fact that the country has a hyper-aging society, which means that Japan will face a substantial increase in the number of elderly cancer patients, according to a review article by Matsuda and Saika published in the Annals of Cancer Epidemiology in 2018. Prof Yasushi Goto of the National Cancer Center...
Concerto HealthAI, the maker of a clinical insight generation platform that employs real-world data in its analyses, is racking up the pharma partnerships as of late. Just weeks after the artificial intelligence company agreed to a multi-year deal with Bristol-Myers Squibb, Concerto announced this morning a similar project with Pfizer that will support the latter’s research on precision oncology...
In an open Nature Communications paper published today, researchers from the University of Michigan described a prototype wearable device that could continuously collect bloodborne cancer cells often used as a biomarker for treatment.
Currently, blood draws are required to identify and examine circulating tumor cells (CTCs), and are often limited by inconsistent CTC counts as well as the health...
Launched in 2010 with a $25 million Series A financing led by Third Rock Ventures, Foundation Medicine released its first commercial assay called FoundationOne in 2012. The company develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumours, hematologic malignancies, and sarcomas. In December 2017, the company’s assay FoundationOne...
Roche announced last week the launch of FoundationOne CDx, Foundation Medicine’s comprehensive companion diagnostic test for personalised cancer care in Singapore. According to the official media release, FoundationOne CDx supports clinicians in their decision-making by providing a clear, in-depth report that describes the unique genomic profile of a patient’s tumour as well as associated,...
The Department of Veterans Affairs and IBM Watson Health have announced a one-year extension to an ongoing public-private partnership applying the AI company’s technology to genomic data for cancer therapy.
The precision oncology collaboration has so far assisted the treatment of more than 2,700 veterans, according to a statement, although the original agreement in 2016 had proposed the lofty...
